CN103735736B - A kind of preparation method and application of the depressed liver-energy dispersing medicine - Google Patents
A kind of preparation method and application of the depressed liver-energy dispersing medicine Download PDFInfo
- Publication number
- CN103735736B CN103735736B CN201410024819.1A CN201410024819A CN103735736B CN 103735736 B CN103735736 B CN 103735736B CN 201410024819 A CN201410024819 A CN 201410024819A CN 103735736 B CN103735736 B CN 103735736B
- Authority
- CN
- China
- Prior art keywords
- medicine
- energy dispersing
- depressed liver
- preparation
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a kind of the depressed liver-energy dispersing medicine; its contained active component is prepared from by following raw materials in part by weight proportioning: fruit of Chinese wolfberry 5-7 part, cape jasmine 5-7 part, Poria cocos 5-7 part, red sage root 5-7 part; and adopt corresponding preparation method; the present invention is nourishing liver and kidney, clearing heat and cooling blood, clearing damp and promoting diuresis, promoting blood circulation and removing blood stasis again; there is the effect of protection chemical damage and treatment fatty liver, and can suppress human glioma cell SF295 propagation.
Description
Technical field
The present invention relates to Chinese medicine preparation technical field, be specifically related to a kind of preparation method and application of the depressed liver-energy dispersing medicine.
Background technology
Along with the continuous improvement of China people living standard, the incidence of disease of domestic hepatopathy raises year by year, comprises chemistry liverThe incidence of disease of damage, fatty liver etc. can be up to 20% left and right; At present, there is no desirable specific treatment medicine for hepatopathy both at home and abroad.The large multiaction of existing conventional anti-hepatic medicine relaxes clinically, therapeutic domain limitation, and curative effect is not remarkable, and some medicines are longPhase use has damage to liver, should not be used for the treatment of hepatopathy, and some medicines also can produce toxic and side effect. For this reason, be badly in need of exploitationGo out the needs that more health foods for the treatment of safely and effectively hepatopathy meet clinical treatment.
Illness rate is high, and recurrence rate height is the main feature of hepatopathy, reflects that the demand in hepatosis treating medicine market is huge simultaneously.Health food is in hepatopathy medication market share critical role, because health food side effect is little, determined curative effect, is applicable to longPhase medication, has adapted to the easily feature of recurrence of hepatopathy, applies very extensive.
Summary of the invention
The object of the present invention is to provide a kind of preparation method and application of the depressed liver-energy dispersing medicine.
Technical scheme of the present invention is:
A kind of the depressed liver-energy dispersing medicine, its contained active component is prepared from by following raw materials in part by weight proportioning: fruit of Chinese wolfberry 5-7 part, cape jasmine5-7 part, Poria cocos 5-7 part, red sage root 5-7 part.
The contained active component of above-mentioned the depressed liver-energy dispersing medicine is prepared from by following raw materials in part by weight proportioning: 6 parts of the fruits of Chinese wolfberry, 6 parts of cape jasmines, Fu6 parts of Siberian cockleburs, 6 parts of the reds sage root.
The preparation process of the depressed liver-energy dispersing medicine is: gets the fruit of Chinese wolfberry, cape jasmine, Poria cocos and the red rooted salvia of recipe quantity and mixes, adding water 2 times,Decoct, collecting decoction, filters, and it is 1.10-1.15 that filtrate is concentrated into relative density, and 65 DEG C of surveys, dry, pulverize into dry extractPowder, adds auxiliary material, makes tablet.
In the preparation process of the depressed liver-energy dispersing medicine, amount of water is to mix 10 times of medicinal material gross weight for the first time, decocts 2-3 hour, adds for the second timeThe water yield is to mix 8 times of water gagings of medicinal material gross weight, decocts 1-2 hour.
The application of the depressed liver-energy dispersing medicine in preparation protection chemical damage health food.
The application of the depressed liver-energy dispersing medicine in preparation treatment fatty liver health food.
The depressed liver-energy dispersing medicine suppresses the application in human glioma SF295 cell proliferation medicine in preparation.
Compared with prior art, the present invention has following beneficial effect:
1. pharmacological research finds that we have protection chemical damage, treatment fatty liver and suppress human glioma cellThe effects such as SF295 propagation, curative effect is reliable, and does not find toxic and side effect. We are because of the traditional Chinese medical science to chemical damage, fatty liverEtiology and pathogenesis and therapy analysis is accurate, compatibility is reasonable has been obtained significant curative effect in clinical treatment.
2. from theory of traditional Chinese medical science, in the depressed liver-energy dispersing medicine of the present invention, the fruit of Chinese wolfberry is nourishing liver and kidney, benefiting shrewd head, cape jasmine heat-clearing, and purging intense heat, coolBlood, has the effects such as the liver of protecting, cholagogic, step-down, calmness, hemostasis, detumescence, be usually used in treating icteric hepatitis, bruise,The disease such as hypertension, diabetes. Poria cocos clearing damp and promoting diuresis, strengthening the spleen and reducing phlegm, antitoxic heart-soothing and sedative, relieves internal heat anticancer. The red sage root is promoting blood circulation and removing blood stasis, fallEffect of fat fat-reducing, calming heart and tranquilizing mind, clearing heat for detumescence. Monarch drug in a prescription in the fruit of Chinese wolfberry and the cape jasmine side of being in side, a benefit one is clear, has soothing the liverSensible effect, Poria cocos is ministerial drug, the merit that principal drug assistance is soothing the liver, the red sage root is promoting blood circulation and removing blood stasis, is adjuvant. Full side is nourishing liver and kidney, clearThe cool blood of heat, clearing damp and promoting diuresis, promoting blood circulation and removing blood stasis again, have the effect of protection chemical damage and treatment fatty liver, and applicant alsoDiscovery can suppress human glioma cell SF295 propagation.
3. actively anti-hepatic generation and development effectively of this problem, this is for the existence and life matter that improve hepatopathy patientsMeasure, protect the health of vast hepatopathy patients, and then improve labour productive forces, significant and higher practical value. ByHigh in this sick incidence of disease, estimate, once marketing application, will produce good Social benefit and economic benefit.
4. Formulation of the present invention is reasonable, and compatibility is rigorous.
5. the present invention consists of dietotherapeutic Chinese medicine, have no side effect, and low price.
Detailed description of the invention
Form by the following examples, is described in further detail foregoing of the present invention again, but this should be interpreted asThe scope of the above-mentioned theme of the present invention only limits to following example, and all technology realizing based on foregoing of the present invention all belong to thisBright scope.
1,, in conjunction with detailed description of the invention, the present invention is further described as follows:
According to the form below, listed weight proportion takes raw material required for the present invention, unit: g
| The fruit of Chinese wolfberry | Cape jasmine | Poria cocos | The red sage root | |
| Embodiment 1 | 500 | 700 | 500 | 700 |
| Embodiment 2 | 700 | 500 | 700 | 500 |
| Embodiment 3 | 600 | 600 | 600 | 600 |
| Embodiment 4 | 500 | 600 | 700 | 600 |
In the present invention, the fruit of Chinese wolfberry, cape jasmine, Poria cocos and the red sage root are pharmacopeia kind.
2, Preparation Example
The preparation of embodiment 1:
Get the fruit of Chinese wolfberry, cape jasmine, Poria cocos and red rooted salvia and mix by upper table, adding water 2 times, decocting, amount of water is for mixed for the first timeClose medicinal material gross weight 10 times, decoct 2 hours, amount of water is 8 times of water gagings that mix medicinal material gross weight for the second time, decocts 2 hoursCollecting decoction, filters, and it is 1.10,65 DEG C of surveys that filtrate is concentrated into relative density, dry, pulverize into dry extract, then addsStarch, mixes, wetting with appropriate 80% ethanol, and softwood processed is crossed 30 mesh sieves and granulated, and is dried in 70～80 DEG C, uses 60 mesh sievesWhole grain, compressing tablet, sugar coating, packing, external packing, censorship is qualified, obtains tablet finished product.
The preparation of embodiment 2:
Get the fruit of Chinese wolfberry, cape jasmine, Poria cocos and red rooted salvia and mix by upper table, adding water 2 times, decocting, amount of water is for mixed for the first timeClose medicinal material gross weight 10 times, decoct 3 hours, amount of water is 8 times of water gagings that mix medicinal material gross weight for the second time, decocts 3Hour collecting decoction, filters, and it is 1.13,65 DEG C of surveys that filtrate is concentrated into relative density, dry, pulverize into dry extract, thenAdd starch, mix, wetting with appropriate 80% ethanol, softwood processed, crosses 30 mesh sieves and granulates, in 70～80 DEG C dry, useThe whole grain of 60 mesh sieves, compressing tablet, sugar coating, packing, external packing, censorship is qualified, obtains tablet finished product.
3 preparations of embodiment:
Get the fruit of Chinese wolfberry, cape jasmine, Poria cocos and red rooted salvia and mix by upper table, adding water 2 times, decocting, amount of water is for mixed for the first timeClose medicinal material gross weight 10 times, decoct 3 hours, amount of water is 8 times of water gagings that mix medicinal material gross weight for the second time, decocts 2Hour collecting decoction, filters, and it is 1.15,65 DEG C of surveys that filtrate is concentrated into relative density, dry, pulverize into dry extract, thenAdd starch, mix, wetting with appropriate 80% ethanol, softwood processed, crosses 30 mesh sieves and granulates, in 70～80 DEG C dry, useThe whole grain of 60 mesh sieves, compressing tablet, sugar coating, packing, external packing, censorship is qualified, obtains tablet finished product.
The preparation of embodiment 4:
Get the fruit of Chinese wolfberry, cape jasmine, Poria cocos and red rooted salvia and mix by upper table, adding water 2 times, decocting, amount of water is for mixed for the first timeClose medicinal material gross weight 10 times, decoct 2 hours, amount of water is 8 times of water gagings that mix medicinal material gross weight for the second time, decocts 2Hour collecting decoction, filters, and it is 1.10,65 DEG C of surveys that filtrate is concentrated into relative density, dry, pulverize into dry extract, thenAdd starch, mix, wetting with appropriate 80% ethanol, softwood processed, crosses 30 mesh sieves and granulates, in 70～80 DEG C dry, useThe whole grain of 60 mesh sieves, compressing tablet, sugar coating, packing, external packing, censorship is qualified, obtains tablet finished product.
3, the experimental study that affects on mouse chemical damage
3.1 animals used as test: Kunming mouse, male, body weight 18-22g, Nanjing Medical University's Experimental Animal Center provides.
3.2 Experimental agents: press preparation method's preparation of above-described embodiment 3, obtain 1000, tablet, specification: 1g/ sheet (quiteContain crude drug 2.4g in every), the self-control of San Ye Bioisystech Co., Ltd of Shenzhen, lot number: 20130512.
Dosage: according to " between humans and animals by the dose,equivalent ratio table of surface conversion ", every day 70 kilograms of people useAmount is for each 2, every day three times, i.e. 6 of every days, adds up to 14.4g, and every day, the consumption of every 20g mouse was14.4*0.0026=0.037g, because every 1g is 2.4g containing crude drug amount, the consumption of every mouse is 0.0156g tablet, forBe convenient to administration, low dose of gavage 0.02g tablet, i.e. middle dosage and high dose gavage 0.04g and 0.08g respectively, every day is everyThe tablet of 20g mouse stomach is respectively 0.05g containing crude drug amount, 0.1g, 0.2g, presses Mice Body restatement, low dosage, inDosage and high dose are respectively 2.5g crude drug amount/kg, 5g crude drug amount/kg and 10g crude drug amount/kg.
Main agents: CCl4Fasten chemical reagent factory product in Hai Xin, before use with refining peanut oil dilution. Lot number: 1205012.ALT (ALT) is measured kit: Bioengineering Research Institute's product is built up in Nanjing, lot number: 20131029; Asparagus fern doorPropylhomoserin aminopherase (AST) is measured kit: Bioengineering Research Institute's product is built up in Nanjing, lot number: 20131019.
3.3 experimentations:
3.3.1 select 50 of healthy mices, separate at random 10 as normal group, all the other 40 mouse are divided into 4 groups at random: mouldType group, high dose group, middle dosage group, low dose group, lumbar injection 0.1%CCl410ml/kg modeling, wherein 4 dosage groupsBy above-mentioned dosage gastric infusion, Normal group and model group be to the water of same volume, every morning 1 time, 30d continuously, fastingAfter 18h, from the blood sampling of mouse posterior orbit veniplex, measure serum aminotransferase activity; And get LH and measure MDA, SOD, GSH-PxThe content of level, and get liver and fix through 10% formaldehyde, pathologic finding is made in HE dyeing.
3.3.2 adopt the statistical method of variance analysis, result shows, compare with normal group, and model group Serum ALT, ASTLevel significantly raises, and difference has conspicuousness (P < 0.01), gives the present invention (2.5,5,10g/kg) group and all can significantly reduce bloodThe ALT, the AST level that in clear, raise, difference has conspicuousness (P < 0.01). In table 1.
Table 1 the present invention is to CCl4Cause the impact (X ± s) of Acute Chemical liver damage model mice Serum ALT, AST
Note: compare * p < 0.05** < 0.01 with model group; Compare with normal group△<0.05△△<0.01
3.3.3 the present invention is to CCl4Cause the impact of Acute Chemical Liver Injury in Mice LH MDA, SOD, GSH-Px levelShow, model group LH MDA level significantly raises, and SOD, GSH-Px level significantly reduce simultaneously, and difference has conspicuousness(P < 0.01). The present invention who gives various dose all can significantly reduce the MDA level raising in LH, and it is even that the while can be improved liverSlurry SOD and GSH-Px level, difference has conspicuousness (P < 0.05); Adopt Ridit analytical method, the HE discovery of dyeing, model groupIn liver, occur the necrosis of spot film piece, bridging necrosis that diffusivity distributes, hepatic sinusoid is obviously congested, dispersivity cell infiltration. The present inventionMiddle heavy dose of group all can alleviate extent of disease and degree, and cell infiltration is reduced.
3.4 the depressed liver-energy dispersing medicine have the good effect that prevents to chemical damage, can be used for the health care of preparation protection chemical damageFood.
4, the experimental study of reducing blood lipid of the present invention:
Animal used as test: Kunming mouse, male, body weight 18-22g, Nanjing Medical University's Experimental Animal Center provides.
Experimental agents: the same, Zhibituo, by Chengdu, Di Aojiuhong pharmaceutical factory produces, and lot number is 0906211, specification: everyGrain dress 0.24g. High lipid food: 10% yolk powder, 1.2% cholesterol, 10% lard, 78% basal feed.
Dosage: the same.
Main agents: T-CHOL (TC), triglycerides (TG), highly dense low lipoprotein cholesterol (HDL-C) and lowDensity lipoprotein (LDL-C) is measured kit, Beijing Zhong Sheng bio-engineering corporation product.
Experimentation: select 60 of healthy mices, separate at random 10 as normal group, all the other 50 mouse, raise with high fatFeed, normally drinking-water, modeling 14d, obtains model group. After model causes, be divided at random 5 groups: model group, high dose group,Middle dosage group, low dose group, positive drug Zhibituo group (340mg/kg), wherein 3 dosage groups, Zhibituo groups are pressed above-mentioned dosageGastric infusion, Normal group and model group are to the water of same volume, and every morning 1 time, 30d, gets the each mouse TC of hematometry continuously,TG, HDL-C, LDL-C, respectively organizes data and represents with means standard deviation, carries out t test between group. The results are shown in Table 2
The impact (n=10) of table 2. the present invention on Experimental Hyperlipemia Mouse Blood ester level
Note: compare * p < 0.05** < 0.01 with model group; Compare with Zhibituo group△<0.05△△<0.01
Conclusion: the present invention can reduce Experimental Hyperlipemia Mouse Blood ester level.
5, clinical research result
Clinical medicine: press preparation method's preparation of above-described embodiment 3, obtain 1000, tablet, also biotechnology of Shenzhen threeCo., Ltd's self-control, lot number: 20130512.
The routine patient of clinical observation 60, male 35 examples, female's 25 examples, in age 40-65 year, the course of disease is the shortest 5 months, the longest 12 years,Fat 46 examples of the bodily form, the history of being addicted to drink 21 examples, hypertension history 16 examples, History of Coronary Heart Disease 13 examples, take each 2 every day three timesSheet.
Diagnostic criteria: (1) Western medicine diagnose standard is with reference to the Diagnosis of Fatty liver standard in Ye Weifa chief editor " clinical liver and bladder disease ".(2) " the disease of tcm Standardization of diagnosis and curative effect " that tcm diagnosis standard is issued with reference to State Administration of Traditional Chinese Medicine, is divided into qi-deficiency type10 examples, caused by hepatic stagnation qi stagnation 12 examples, liver gallbladder damp-heat type 10 examples, deficiency of the kidney yin type 7 examples, type of deficiency of YIN leading to hyper activity of YANG 11 examples, phlegm becomes silted up and hands overResistance type 10 examples. There is in various degree spiritlessness and weakness in most of patients, poor appetite, and tiredness with no desire to speak, uncomfortable liver area, large loose stool is thin,Dark tongue quality tongue is thick greasy.
Curative effect judgement:
Cure: cardinal symptom disappears, hepatomegaly disappears or retraction, and hepatic region is without obvious tenderness or percussion pain, and liver function is normal, superAcoustic echo figure and ultrasonogram are normal, and blood fat is tending towards normally or obviously improves Body weight loss.
Take a turn for the better: cardinal symptom disappears substantially, and hepatomegaly is recovered to some extent, and ultrasonoscopy is clearly better, and blood fat makes moderate progress, body weightDecline to some extent.
Invalid: symptom, sign, chemical examination, ultrasonoscopy and body weight are without changer.
The results are shown in Table 3
The observation of curative effect of table 3. the present invention to fatty liver patient
The present invention is through clinical practice, tool patient's the weak effect of the right distending pain in hypochondrium, abdominal distension that has clear improvement, and there is fat-reducing and fallFat, improve liver function, the effect for the treatment of fatty liver. By finding out medicine of the present invention in table, in 60 examples, curing number is 35 examples,Good revolution is 20 examples, and invalid is 5 examples, and total effective rate is 91.7%, in taking, has no adverse reaction.
6, the depressed liver-energy dispersing medicine suppresses the experimental study data of human glioma SF295 cell proliferation
6.1 experiment material
6.1.1 experiment cell line: human glioma SF295 cell, Nanjing Medical University's laboratory cell bank, DMEM+10%FBS cellar culture.
6.1.2 Experimental agents
Drugs: the depressed liver-energy dispersing medicine of the present invention: press embodiment 3 method preparations, the self-control of San Ye Bioisystech Co., Ltd of Shenzhen,Lot number: 20130512.
Liquid liquid storage: take 100mg the depressed liver-energy dispersing medicine, be dissolved in 5ml absolute ethyl alcohol, 0.2 μ m filter filters, 500 μ ldoffPipe packing ,-20 DEG C of storages, 0.2 μ m filter filters the use of absolute ethyl alcohol in order to control group simultaneously.
6.1.3 experiment reagent
The Cat.No.12100-061Lot.No.758137 of DMEM(GIBCO company); Hyclone (Hangzhoupro, sky, Zhejiang biologyThe Lot.No.100419 of Science and Technology Ltd.); NaHCO3(Shanghai hundred million Cat.No.11810-033 of chemical reagent Co., Ltd of a specified durationLot.No.1088387); Trypsin(AMRESCO company lot number: 2010/04); EDTA(AMRESCO company criticizesNumber: 2009/10); PenicillinGSodiumSalt(AMRESCO company lot number: 2010242); StreptomycinSulfate(AMRESCO company lot number: 2010382); Absolute ethyl alcohol (Nanjing Chemistry Reagent Co., Ltd.'s lot number: 080310182);MTT (Biosharp lot number: 0793); PBS(laboratory autogamy);
6.1.4 experiment equipment
Lycra inverted microscope (German Leica model: DM1L); Visible-ultraviolet light microwell plate detector (U.S. MD public affairsModel: the SPECTRAMAX190 of department); CO2 incubator (FORMA model: 3111); Super-clean bench (Su Jing group peaceSafe company manufactures model: SW-CJ-ZFD); Pure water instrument (Spring company of U.S. model: S/N020579); Precision is moved liquidDevice (French Gilson Inc model: P2); Electronic balance (German Sai Duolisi Co., Ltd model: BT323S); EntirelyAutomatic high pressure autoclave (Japanese SANYO company model: MLS-3020); Table electrothermal air dry oven (Shanghai precisionExperimental facilities company model: DHG9123A); Refrigerator (Siemens Company's model: KG18V21TI); Liquid nitrogen container (CBSModel: 2001); Low speed centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000); 0.2 μ m filter (MILLIPOREModel: SLGP033RB); 10cm culture dish (NEST company), 96 well culture plates (NEST company); Cell counting count board;Centrifuge tube, pipette, Tips are some.
6.2 experimental technique
1) SF295 cell carries out cellar culture (10cm culture dish) with DMEM+10%FBS in 37 DEG C, 5%CO2,When Growth of Cells is during to logarithmic phase, collecting cell, discards nutrient solution, and PBS fine laundering 3 times, adds 3ml0.25% trypsase-0.04%EDTA, after 37 DEG C of digestion 2min, adds 5ml complete medium neutralization reaction wherein, will after piping and druming cellIt proceeds in centrifuge tube, and the centrifugal 5min of 1000rpm adjusts 3 × 104/ml of concentration of cell suspension.
2) cell kind is entered in 96 well culture plates, every hole adds cell suspension 180 μ l, and culture plate is put into cell culture incubator(37 DEG C, 5%CO2) cellar culture.
3) according to Growth of Cells situation, generally grow to 50%-70%, add the depressed liver-energy dispersing medicine solution, continue to cultivate 24h.
4) after 24h, add 20 μ lMTT solution (5mg/ml, i.e. 0.5%MTT), continue to cultivate 4h.
5) after 4h, buckle method is removed supernatant, pats dry gently with blotting paper, and every hole adds 200 μ l dimethyl sulfoxide (DMSO)s, puts on shaking tableLow-speed oscillation 10min, fully dissolves crystal. Measure the light absorption value in each hole at enzyme-linked immunosorbent assay instrument 490nm place.
6) background (do not add cell, only add nutrient solution) is set simultaneously, control wells (the medicine dissolving medium of cell, same concentrations,Nutrient solution, MTT, dimethyl sulfoxide (DMSO)), set 6 multiple holes for every group.
7) result represents the inhibiting rate of cell with medicine:
Cell increment inhibiting rate (%)=(control wells OD value-dosing holes OD value)/control wells OD value × 100%. Experiment repeats 3Inferior.
6.3 statistical disposition
Adopt correlation analysis and Studentt inspection in MicrosoftExcel2003 software, data represent with mean ± S.D..
6.4 experimental result
Statistical result showed after mtt assay experiment, with control group comparison, in the time that dosage reaches 5mg/ml, to SF295 cellPropagation suppresses variant (P < 0.05), and dosage this difference in the time of 10mg/ml has conspicuousness (P < 0.01), when dosage reaches 15-20When mg/ml, there is utmost point significant difference (P < 0.001).
Table 4 the depressed liver-energy dispersing medicine is on SF295 cell inhibitory effect impact research (X ± SD)
Note: with control group comparison, * P < 0.01; * P < 0.001
6.5 experiment conclusion
The depressed liver-energy dispersing medicine can suppress SF295 cell proliferation, reduces the Growth of Cells number of SF295 cell, and this effect is dose dependent.
Claims (4)
1. the depressed liver-energy dispersing medicine suppresses the application in human glioma SF295 cell proliferation medicine in preparation, it is characterized in that,The contained active component of the depressed liver-energy dispersing medicine is prepared from by following raw materials in part by weight proportioning: fruit of Chinese wolfberry 5-7 part, cape jasmine 5-7 part,Poria cocos 5-7 part, red sage root 5-7 part.
2. the depressed liver-energy dispersing medicine suppresses answering in human glioma SF295 cell proliferation medicine in preparation as claimed in claim 1With, it is characterized in that, the contained active component of the depressed liver-energy dispersing medicine is prepared from by following raw materials in part by weight proportioning: 6 parts of the fruits of Chinese wolfberry,6 parts of cape jasmines, 6 parts, Poria cocos, 6 parts of the reds sage root.
3. the depressed liver-energy dispersing medicine suppresses in human glioma SF295 cell proliferation medicine in preparation as claimed in claim 1 or 2Application, it is characterized in that, the preparation process of the depressed liver-energy dispersing medicine is: the fruit of Chinese wolfberry, cape jasmine, Poria cocos and the Salvia miltiorrhiza of getting recipe quantityMaterial also mixes, and adds water 2 times, decocts, and collecting decoction, filters, and it is 1.10-1.15 that filtrate is concentrated into relative density, 65 DEG CSurvey, dry, pulverize into dry extract, add auxiliary material, make tablet.
4. the depressed liver-energy dispersing medicine suppresses answering in human glioma SF295 cell proliferation medicine in preparation as claimed in claim 3With, it is characterized in that in the preparation process of the depressed liver-energy dispersing medicine that amount of water is for the first time to mix 10 times of medicinal material gross weight, decocts 2-3Hour, amount of water is 8 times of water gagings that mix medicinal material gross weight for the second time, decocts 1-2 hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410024819.1A CN103735736B (en) | 2014-01-20 | 2014-01-20 | A kind of preparation method and application of the depressed liver-energy dispersing medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410024819.1A CN103735736B (en) | 2014-01-20 | 2014-01-20 | A kind of preparation method and application of the depressed liver-energy dispersing medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103735736A CN103735736A (en) | 2014-04-23 |
| CN103735736B true CN103735736B (en) | 2016-05-04 |
Family
ID=50492851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410024819.1A Active CN103735736B (en) | 2014-01-20 | 2014-01-20 | A kind of preparation method and application of the depressed liver-energy dispersing medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103735736B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104474171A (en) * | 2014-11-17 | 2015-04-01 | 辛振学 | Traditional Chinese medicine preparation for treatment of neuroglioma |
| CN113397014A (en) * | 2021-06-29 | 2021-09-17 | 深圳市三也生物科技有限公司 | Preparation method of health tea granules |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416842A (en) * | 2001-10-30 | 2003-05-14 | 上海中西药业股份有限公司 | Liver protecting compound prepn and its prepn process |
-
2014
- 2014-01-20 CN CN201410024819.1A patent/CN103735736B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416842A (en) * | 2001-10-30 | 2003-05-14 | 上海中西药业股份有限公司 | Liver protecting compound prepn and its prepn process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103735736A (en) | 2014-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988827B (en) | Dendrobium officinale granula | |
| CN102988828A (en) | Preparation method of dendrobium officinale granula | |
| CN103735736B (en) | A kind of preparation method and application of the depressed liver-energy dispersing medicine | |
| CN105106816A (en) | Traditional Chinese medicine healthcare preparation with protection effect on chemical liver injury and preparing method thereof | |
| CN102085248A (en) | Traditional Chinese medicinal composition for treating cervix diseases, method for preparing same and method for detecting same | |
| CN101972334B (en) | Traditional Chinese medicine preparation for preventing and treating infantile eczema and preparation method thereof | |
| CN101019897B (en) | Antitumor medicine composition and its preparation method | |
| CN105145957B (en) | A kind of health-care herbal tea beverage improving oral ulcer and preparation method thereof and detection method | |
| CN102008563B (en) | Anticancer traditional Chinese medicine and preparation method thereof | |
| CN101461894A (en) | Medicament composition for treating female climacteric syndrome and delaying age | |
| CN102309630A (en) | Processing method for toxicity reduction and efficacy enhancement of rhizoma alismatis | |
| CN106974981A (en) | A kind of external used medicine of analgesic | |
| CN101574384A (en) | Production method for preparing anti-cancer medicament preparation and health care food by taking fibrous ginseng root as raw material | |
| CN105884841B (en) | A kind of preparation method of phenylpropanoids | |
| CN105663150B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation | |
| CN103191197B (en) | Targeting formula antitumor anticancer agent and preparation method thereof | |
| CN105732736B (en) | A kind of preparation method of phenylpropanoids | |
| CN106046071B (en) | A kind of preparation method of phenylpropanoids | |
| CN104825922A (en) | Traditional Chinese medicine composition with anti-colorectal cancer activity and preparation method and application of traditional Chinese medicine composition | |
| CN102068537B (en) | The preparation of Pericarpium Citri Reticulatae Radix Glycyrrhizae prevents and treats the health food of nasopharyngeal carcinoma and the production method of medicine | |
| CN103897050A (en) | Sepia anti-prostate cancer polypeptide and preparation method thereof | |
| CN108186990A (en) | It is a kind of to be used to treat big drug of children's mesenteric adenophyma and preparation method thereof | |
| CN102824385A (en) | Aralia tengyuch euonymus bark total saponin and preparation method and application thereof | |
| CN113633712B (en) | Traditional Chinese medicine composition for treating gout and oral preparation based on traditional Chinese medicine composition | |
| CN105535685A (en) | Compound traditional Chinese medicine for resisting colon cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |